[Analysis of antineoplastic drugs used in Cancer Center, Sun Yat-sen University, during the period of 1996-2005].
OBJECTIVE
Lately, the prevention, treatment and research of cancer have developed rapidly. Antineoplastic drugs have become one of the major measures for cancer therapy. Many new antineoplastic drugs have been discovered and prepared, and used to treat tumors. Cancer Center of Sun Yat-sen University is one of the biggest cancer hospitals in South China. The use of antineoplastic drugs of this center can reflect changes in this area. This study was to analyze and evaluate the situation and trend of antineoplastic drugs used in Cancer Center, Sun Yat-sen University from 1996 and 2005, in order to provide references for the rational use of drugs in clinical application.


METHODS
Consumption of antineoplastic drugs was analyzed by sum and defined daily dose (DDDs) ranking.


RESULTS
The costs of antineoplastic drugs occupied 31.0%-48.8% of all drugs from 1996 to 2005; and the average increasing ratio is 21.5%. The cost rate of anti-cancer vegetable drugs and other genus increased the quickest, while the total costs of alkylate increased the slowest during the ten years. Some new monoantibodies and gene drugs were continuously applied in clinical use.


CONCLUSIONS
The direction of the research and development of antineoplastic drugs is towards high efficiency, low toxicity and individualized use.
Zhong
Jin-Tang
JT
State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, P. R. China.
Huang
Hong-Bing
HB
Lin
Zi-Chao
ZC
Liu
Tao
T
Lin
Pei-Liang
PL
D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000964:Antimetabolites, Antineoplastic / Q000191:economics* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000191:economics* / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000191:economics* / Q000627:therapeutic use; D016190:Carboplatin / Q000191:economics / Q000627:therapeutic use; D002681:China; D002945:Cisplatin / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000191:economics / Q000627:therapeutic use; D016527:Drug Costs / Q000639:trends; D017723:Drug Utilization Review; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D017239:Paclitaxel / Q000191:economics / Q000627:therapeutic use; D000069283:Rituximab; D014747:Vinblastine / Q000031:analogs & derivatives / Q000191:economics / Q000627:therapeutic use; D000077235:Vinorelbine; D000093542:Gemcitabine
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D003841:Deoxycytidine; D000069283:Rituximab; D014747:Vinblastine; D016190:Carboplatin; D017239:Paclitaxel; D002945:Cisplatin; D000077235:Vinorelbine; D000093542:Gemcitabine